# A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05585320/  
OnCo record `nct05585320` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Dabrafenib, Pembrolizumab in melanoma and non-small-cell lung cancer, run by Immuneering Corporation, active and no longer recruiting.

## Summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05585320 by Immuneering Corporation, with 209 participants enrolled, started 2022-10-31 and due to reach its primary completion in 2026-06. Interventions recorded: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E). Conditions listed: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05585320
- Phase: 1/2
- Setting: A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors
- Sponsor: Immuneering Corporation
- Enrolled: 209

## Sources

- ClinicalTrials.gov NCT05585320: https://clinicaltrials.gov/study/NCT05585320

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Immuneering](https://onco.cc/companies/immuneering/)

---
JSON: https://onco.cc/api/v1/entities/nct05585320.json